Clinical overview of the taxanes

Pharmacotherapy

Volumn 17, Issue 5 II SUPPL., 1997, Pages

  Goldspiel, Barry R ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; DOXORUBICIN; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG USE; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; OVARY CANCER; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; TAXOIDS;

EID: 0030879715     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (156)

1. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet 1994;344:1267-72.
2. Spencer CM, Faulds D. Paclitaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994;48:794-847.
3. Fulton B, Spencer CM. Docetaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs 1996;51:1075-92.
4. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry, and composition Biochemistry 1993;32:2747-55.
5. Fromes Y, Gounon P, Bissery MC, et al. Differential effects of Taxol and Taxotere (RP56976, NSC628503) on tau and MAP2 containing microtubules [abstr]. Proc Am Assoc Cancer Res 1992;33:511.
6. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2:1843-9.
7. Klauber N, Parangi S, Flynn E, et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol. Cancer Res 1997;57:81-6.
8. Blagosklonny MV, Schulte T, Nguyen P, et al. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 1996;56:1851-4.
9. Milross CG, Mason KA, Hunter NR, et al. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 1996;88:1308-14.
10. Choy H, Rodriguez FF, Koester S, et al. Investigation of Taxol as a potential radiation sensitizer. Cancer 1993;71:3774-8.
11. Tishler RB, Geard CR, Hall EJ, et al. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 1992;52:3495-7.
12. Barber HRK. New frontiers in ovarian cancer diagnosis and management. Yale J Biol Med 1991;64:127-41.
13. Ozols RF, Vermorken JB. Chemotherapy of advanced ovarian cancer: current status and future directions. Semin Oncol 1997;24(1 suppl 2):S2-1-9.
14. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
15. Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL. Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992;10:1748-53.
16. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-66.
17. Kohn EC, Sarosy G, Bicher A, et al. Dose-intense Taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994;86:18-24.
18. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-9.
19. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994;12:1748-53.
20. Trimble EL, Adams JD, Vena D, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993;11: 2405-10.
21. Francis P, Schneider J, Hann L, et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994;12:2301-8.
22. Kavanagh JJ, Kudelka AP, de Leon CG, et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 1996;2:837-42.
23. Piccart MJ, Gore M, ten Bokkel Huinink, et al. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 1995;87:676-81.
24. Kaye SB, Piccart M, Aapro M, et al. Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. Eur J Cancer 1995;31A(suppl 4):S14-17.
25. Thigpen T, Vance RB, McGuire WP, Hoskins WJ, Brady M. The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience. Semin Oncol 1995;22(6 suppl 14):23-31.
26. Omura GA, Brady MF, Delmore JE, et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study [abstr]. Proc Am Soc Clin Oncol 1996;15:280.
27. Abu-Rustum NR, Aghajanian C, Barakat RR, et al. Salvage weekly paclitaxel (Taxol) for recurrent ovarian cancer [abstr]. Proc Am Soc Clin Oncol 1997;16:364a.
28. Fennelly D, Aghajanian C, Shapiro F, et al. Phase 1 and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997;15:187-92.
29. Klaassen U, Wilke H, Strumberg D, et al. Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer 1996;32A:547-9.
30. Verschraegen C, Kudelka A, Steger M, et al. Randomized phase II study of two dose levels of docetaxel in patients with advanced epithelial ovarian cancer who have failed paclitaxel chemotherapy [abstr]. Proc Am Soc Clin Oncol 1997;16:381a.
31. Noda K, Fujiwara K, Kohno I, et al. Dose escalation phase (P) II trial of docetaxel in ovarian cancer patients (pts) with one prior platinum-based chemotherapy: a new study design to find an effective dose with acceptable toxicities of anticancer drugs [abstr]. Proc Am Soc Clin Oncol 1997;16:374a.
32. Coeffic D, Antoine EC, Benhammouda A, et al. Cisplatin (P), paclitaxel (T), and cyclophosphamide (C) (PTC) combination chemotherapy in advanced ovarian cancers (AOC): results of a phase II study of 30 patients [abstr]. Proc Am Soc Clin Oncol 1997;16:367a.
33. Kohn EC, Sarosy GA, Davis P, et al. A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer. Gynecol Oncol 1996;62:181-91.
34. Huizing MT, van Warmerdam JC, Rosing H, et al. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. J Clin Oncol 1997;15:1953-64.
35. Alberts DS, Green S, Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992;10:706-17.
36. Swenerton K, Jeffrey J, Stuart G, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992;10:718-26.
37. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
38. Bolis G, Scarfone G, Villa A, Acerboni S, Siliprandi V, Guarnerio P. A phase I trial with fixed-dose carboplatin and escalating doses of paclitaxel in advanced ovarian cancer. Semin Oncol 1997;24(1 suppl 2):S2-23-5.
39. Bookman MA, McGuire WP III, Kilpatrick D, et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 1996;14:1895-902.
40. Meerpohl H-G, du Bois A, Lück HJ, et al. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase 1 trial. Semin Oncol 1997;24(1 suppl 2):S2-17-22.
41. ten Bokkel Huinink W, Veenhof C, Huizing M, et al. Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study. Semin Oncol 1997;24(1 suppl 2):S2-31-3.
42. Waltzman R, Phatak N, Venkatraman E, et al. Efficacy of platinum/taxane primary therapy for ovarian cancer [abstr]. Proc Am Soc Clin Oncol 1997;16:381a.
43. du Bois A, Nitz U, Schröder W, et al. Cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line chemotherapy in ovarian cancer: interim analysis of an AGO Study Group trial [abstr]. Proc Am Soc Clin Oncol 1997;16:357a.
44. Neijt JP, Hansen M, Hansen SW, et al. Randomized phase III study in previously untreated ovarian cancer FIGO stage IIB, IIC, III, IV comparing paclitaxel-cisplatin and paclitaxel-carboplatin [abstr]. Proc Am Soc Clin Oncol 1997;16:352a.
45. Vasey PA, Eggleton SPH, Birt A, et al. A feasibility study of a Taxotere/cisplatin combination for previously untreated advanced epithelial ovarian cancer [abstr]. Proc Am Soc Clin Oncol 1997;16:356a.
46. Jakobsen E, Bertelsen K, Madsen EL, et al. Phase I-II study in advanced ovarian cancer with docetaxel (Taxotere), cisplatin and cyclophosphamide [abstr]. Proc Am Soc Clin Oncol 1997;16:371a.
47. Mouridsen HT. Systemic therapy of advanced breast cancer. Drugs 1992;44(suppl 4):17-28.
48. Harris J, Morrow M, Norton L. Malignant tumors of the breast. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology, 5th ed. Philadelphia: Lippincott-Raven, 1997:1557-1616.
49. Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797-805.
50. Davidson NG. Single-agent paclitaxel as first-line treatment of metastatic breast cancer: the British experience. Semin Oncol 1996;23 (5 suppl 11):6-10.
51. Reichman BS, Seidman AD, Crown JPA, et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993;11:1943-51.
52. Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995;13:2575-81.
53. Gianni L, Munzone E, Capari G, et al. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995;87:1169-75.
54. Abrams JS, Vena DA, Baltz J, et al. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial. J Clin Oncol 1995;13:2056-65.
55. Nabholtz J-M, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996;14:1858-67.
56. Seidman AD, Reichman BS, Crown JPA, et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995;13:1152-9.
57. Paridaens R, Bruning P, Klijn J, et al. An EORTC crossover trial comparing single-agent Taxol (T) and doxorubicin (D) as first-and second-line chemotherapy (CT) in advanced breast cancer (ABC) [abstr]. Proc Am Soc Clin Oncol 1997;16:154a.
58. Sledge GW Jr, Neuberg D, Ingle J, Martino S, Wood W. Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial [abstr]. Proc Am Soc Clin Oncol 1997;16:1a.
59. Bishop JF, Dewar J, Tattersall MHN, et al. Taxol (paclitaxel) alone is equivalent to CMFP combination chemotherapy as frontline treatment in metastatic breast cancer [abstr]. Proc Am Soc Clin Oncol 1997;16:153a.
60. Raymond E, Hanauske A, Faivre S, et al. Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming units. Anti-Cancer Drugs 1997;8:379-85.
61. Wilson WH, Berg SL, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994;12:1621-9.
62. Seidman AD, Hochhauser D, Gollub M, et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996;14:1877-84.
63. Seidman AD, Murphy B, Hudis C, et al. Activity of Taxol (T) by weekly 1 hour infusion in patients (pts) with metastatic breast cancer (MBC): a phase II and pharmacologic study [abstr]. Proc Am Soc Clin Oncol 1997;16:148a.
64. Sikov W, Akerley W, Cummings F, et al. High-dose weekly paclitaxel for locally advanced (LABC) and metastatic breast cancer (MBC) [abstr]. Proc Am Soc Clin Oncol 1997;16:191a.
65. Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995;13:314-22.
66. Fumoleau P, Chevallier B, Kerbrat P, et al. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol 1996;7:165-71.
67. Hudis CA, Seidman AD, Crown JPA, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:58-65.
68. Trudeau ME, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996;14:422-8.
69. -2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. Br J Cancer 1996;74:650-6.
70. Ravdin PM, Burris HA III, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13:2879-85.
71. ten Bokkel Huinink WW, Prove AM, Piccart M, et al. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer: a study of the EORTC Early Clinical Trials Group. Ann Oncol 1994;5:527-32.
72. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13:2886-94.
73. Adachi I, Watanabe T, Takashima S, et al. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 1996;73:210-16.
74. Chan S, Friedrichs K, Noël D, et al. A randomized phase III study of Taxotere (T) versus doxorubicin (D) in patients (pts) with metastatic breast cancer (MBC) who have failed an alkylating containing regimen: preliminary results [abstr]. Proc Am Soc Clin Oncol 1997;16:154a.
75. Rhône-Poulenc Rorer. Taxotere (docetaxel) for injection concentrate package insert. Collegeville, PA; 1996.
76. Nabholtz J-M, Theurlimann B, Bezwoda WR, et al. Taxotere (T) versus mitomycin C + vinblastine (MV) in patients (pts) with metastatic breast cancer (MBC) who have failed an anthracycline containing regimen: preliminary results of a randomized phase III study [abstr]. Proc Am Soc Clin Oncol 1997;16:148a.
77. Valero V, Burris HA III, Jones SE, et al. Multicenter pilot study of Taxotere in Taxol-resistant metastatic breast cancer (MBC) [abstr]. Proc Am Soc Clin Oncol 1996;15:107.
78. Holmes FA. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review. Semin Oncol 1996;23(5 suppl 11):46-56.
79. Amadori D, Frassineti GL, Zoli W, et al. A phase I/II study of paclitaxel and doxorubicin in the treatment of advanced breast cancer. Semin Oncol 1996;23(1 suppl 1):19-23.
80. Dombernowsky P, Gehl J, Boesgaard M, Paaske T, Jensen BV. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Semin Oncol 1996;23(5 suppl 11):23-7.
81. Holmes FA, Valero V, Walters RS, et al. The M.D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. Monogr Natl Cancer Inst 1993;15:161-9.
82. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995;13:2688-99.
83. Gianni L, Viganò L, Locatelli A, et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 1997;15:1906-15.
84. Gelmon KA, O'Reilly SE, Tolcher AW, et al. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol 1996;14:1185-91.
85. Perez EA, Hartmann LC. Paclitaxel and carboplatin for advanced breast cancer. Semin Oncol 1996;23(5 suppl 11):41-5.
86. Sparano JA, Neuberg D, Glick JH, et al. Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1997;15:1880-4.
87. Wasserheit C, Frazein A, Oratz R, et al. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J Clin Oncol 1996;14:1993-9.
88. Klaassen U, Wilke H, Seeber S. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer. Semin Oncol 1996;23(5 suppl 11):32-7.
89. Paul DM, Garrett AM, Meshad M, DeVore RD, Porter LL, Johnson DH. Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience. Semin Oncol 1996;23(1 suppl 1):48-52.
90. Michelotti A, Gennari A, Salvadori B, et al. Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients. Semin Oncol 1996;23(5 suppl 11):38-40.
91. McCaskill-Stevens WJ, Fox S, Harlan J, Sledge WG. Phase I/II study of biweekly paclitaxel (P) and carboplatin (C) in the treatment of patients (pts) with stage IV breast carcinoma [abstr]. Proc Am Soc Clin Oncol 1997;16:183a.
92. Burris HA III, Fields S, Peacock N. Docetaxel (Taxotere) in combination: a step forward. Semin Oncol 1995;22(6 suppl 13):35-40.
93. Verweij J, Planting ASTh, van der Burg MEL, et al. A phase I study of docetaxel (Taxotere) and cisplatin in patients with solid tumors [abstr]. Proc Am Soc Clin Oncol 1994;13:148.
94. Antoine EC, Coeffic D, Gozy M, et al. A phase II study of docetaxel (T) and cisplatin (P) in anthracycline (A)-pretreated metastatic breast cancer (PMBC): preliminary results [abstr]. Proc Am Soc Clin Oncol 1997;16:148a.
95. Llombart-Cussac A, Spielmann M, Dohollou N, Le Cesne A, Rixe O. Cis-platinum-Taxotere phase I/II trial in patients with anthracyclin-resistant advanced breast cancer (ABC) [abstr]. Proc Am Soc Clin Oncol 1997;16:180a.
96. Sano M, Adachi I, Watanabe T, et al. A phase I/II study of docetaxel (TXT) in combination with continuous infusion of fluorouracil (5-FU) in patients with advanced or recurrent breast cancer [abstr]. Proc Am Soc Clin Oncol 1997;16:189a.
97. Early Breast Cancer Trialists' Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15.
98. Hudis CA, Seidman AD, Baselga J, et al. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes. Semin Oncol 1995;22(6 suppl 15):18-23.
99. Hudis CA, Seidman A, Raptis G, et al. Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience. Semin Oncol 1996;23(1 suppl 1):58-64.
100. Buzdar AU, Morris A, Hortobagyi GN, et al. Prospective randomized trial of Taxol (Tax) alone versus flurouracil, doxorubicin, cyclophosphamide (FAC) as an induction therapy in patients with operable breast cancer [abstr]. Proc Am Soc Clin Oncol 1997;16:141a.
101. Stewart LA, Pignon JP, Parmar MKB, et al. A meta-analysis using individual patient data from randomised clinical trials (RCTS) of chemotherapy (CT) in non-small cell lung cancer (NSCLC): (3) survival in the supportive care (SC) setting [abstr]. Proc Am Soc Clin Oncol 1994;13:337.
102. Eisenhauer EA. Taxol in advanced non-small-cell lung cancer: plus ça change? J Natl Cancer Inst 1993;85:346-7.
103. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993;85:388-94.
104. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993;85:384-8.
105. Millward MJ, Bishop JF, Friedlander M, et al. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 1996;14:142-8.
106. Rosell R, González-Larriba JL, Alberola V, et al. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small-cell lung cancer: links between p53 and K-ras gene status and chemosensitivity. Semin Oncol 1995;22(6 suppl 14): 12-8.
107. Hainsworth JD, Greco FA. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy. Semin Oncol 1995;22(6 suppl 15):45-9.
108. Murphy WK, Winn RJ, Huber M, et al. Phase II study of Taxol (T) in patients (pts) with non-small cell lung cancer (NSCLC) who have failed platinum (P) containing chemotherapy (CTX) [abstr]. Proc Am Soc Clin Oncol 1994;13:363.
109. Ruckdeschel J, Wagner H Jr, Williams C, et al. Second-line chemotherapy for resistant, metastatic, non-small cell lung cancer (NSCLC): the role of Taxol (TAX) [abstr]. Proc Am Soc Clin Oncol 1994;13:357.
110. Bonomi P, Kim K, Chang A, et al. Phase III trial comparing etoposide (E) cisplatin (C) versus Taxol (T) with cisplatin-G-CSF (G) versus Taxol-cisplatin in advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group trial [abstr]. Proc Am Soc Clin Oncol 1996;15:382.
111. Johnson DH, Paul DM, Hande KR, et al. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 1996;14:2054-60.
112. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995;13:1860-70.
113. Akerley W, Choy H, Glantz M, et al. Phase II trial of weekly paclitaxel for advanced non-small cell lung cancer (NSCLC) [abstr]. Proc Am Soc Clin Oncol 1997;16:450a.
114. Niell HG, Miller AA, Kumar P, Griffin JP. Phase I/II trial of paclitaxel (TAX), cisplatin (DDP) and radiation therapy for stage III non-small cell lung cancer (NSCLC) [abstr]. Proc Am Soc Clin Oncol 1997;16:447a.
115. Cerny T, Kaplan S, Pavlidis N, et al. Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG). Br J Cancer 1994;70:384-7.
116. Fossella FV, Lee JS, Murphy WK, et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 1994;12:1238-44.
117. Francis PA, Rigas JR, Kris MG, et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994;12:1232-7.
118. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 1995;75:968-72.
119. Kunitoh H, Watanabe K, Onoshi T, Furuse K, Niitani H, Taguchi T. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J Clin Oncol 1996;14:1649-55.
120. Burris H, Eckardt J, Fields S, et al. Phase II trials of Taxotere in patients with non-small cell lung cancer [abstr]. Proc Am Soc Clin Oncol 1993;12:335.
121. Fossella FV, Lee JS, Shin DM, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 1995;13:645-51.
122. Cole JT, Gralla RJ, Marques CB, Rittenberg CN. Phase I-II study of cisplatin + docetaxel (Taxotere) in non-small cell lung cancer (NSCLC) [abstr]. Proc Am Soc Clin Oncol 1995;14:357.
123. Belani CP, Bonomi P, Dobbs T, et al. Multicenter phase II trial of docetaxel and cisplatin combination in patients with non-small cell lung cancer [abstr]. Proc Am Soc Clin Oncol 1997;16:462a.
124. Early E, Miller VA, Grant SC, Pizzo B, Heelan RT, Kris MG. Phase I/II trial of docetaxel (DTX) and vinorelbine (VNR) with filgrastim (G-CSF) in patients (pts) with advanced non-small cell lung cancer (NSCLC) [abstr]. Proc Am Soc Clin Oncol 1997;16:467a.
125. Ettinger DS. Single-agent paclitaxel in the treatment of small cell lung cancer. Semin Oncol 1996;23(6 suppl 16):16-17.
126. Nair S, Marschke R, Grill J, et al. A phase II study of paclitaxel (Taxol) and cisplatin (CDDP) in the treatment of extensive stage small cell lung cancer (ESSCLC) [abstr]. Proc Am Soc Clin Oncol 1997;16:454a.
127. Glisson BS, Kurie JM, Fox NJ, et al. Phase I-II study of cisplatin, etoposide, and paclitaxel (PET) in patients with extensive small cell lung cancer (ESCLC) [abstr]. Proc Am Soc Clin Oncol 1997;17:455a.
128. Smyth JF, Smith IE, Sessa C, et al. Activity of docetaxel (Taxotere) in small cell lung cancer. Eur J Cancer 1994;30A:1058-60.
129. Latreille J, Cormier Y, Martins H, Goss G, Fisher B, Eisenhauer EA. Phase II study of docetaxel (Taxotere) in patients with previously untreated extensive small cell lung cancer. A trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). Invest New Drugs 1996;13:343-5.
130. Schantz SP, Harrison LB, Forastiere AA. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology, 5th ed. Philadelphia: Lippincott-Raven, 1997:741-61.
131. Forastiere AA. Current and future trials of TAXOL (paclitaxel) in head and neck cancer. Ann Oncol 1994;5(suppl 6):S51-4.
132. Smith RE, Thornton DE, Allen J. A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol 1995;22(3 suppl 6):41-6.
133. Forastiere AA, Leong T, Murphy B, et al. A phase III trial of high-dose paclitaxel + cisplatin + G-CSF versus low-dose paclitaxel + cisplatin in patients with advanced squamous cell carcinoma of the head and neck (HNSCC): an Eastern Cooperative Oncology Group trial [abstr]. Proc Am Soc Clin Oncol 1997;16:384a.
134. Hitt R, Hornedo J, Colomer R, et al. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results. Semin Oncol 1995;22(6 suppl 15):50-4.
135. Fountzilas G, Athanassiadis A, Samantas E, et al. Paclitaxel and carboplatin in recurrent or metastatic head neck cancer: a phase II study. Semin Oncol 1997;24(1 suppl 2):S2-65-7.
136. Hainsworth JD, Peacock NW, Thomas M, Erland JB, Hopkins LG, Greco FA. Paclitaxel, carboplatin and prolonged infusion 5-FU in the treatment of advanced squamous cancer: a phase II trial [abstr]. Proc Am Soc Clin Oncol 1997;16:401a.
137. Shin DM, Glisson BS, Huber M, et al. Phase I/II study of paclitaxel (T), ifosfamide (I), and cisplatin (P) combination chemotherapy in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) [abstr]. Proc Am Soc Clin Oncol 1996;15:312.
138. Catimel G, Verweij J, Mattijssen V, et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994;5:533-7.
139. Dreyfuss AI, Clark JR, Norris CM, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996;14:1672-8.
140. Posner M, Norris C, Colevas A, et al. Phase I/II trial of docetaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) for curable, locally advanced squamous cell cancer of the head and neck (SCCHN) [abstr]. Proc Am Soc Clin Oncol 1997;16:387a.
141. Forastiere AA, Neuberg D, Taylor SG IV, et al. Phase II evaluation of Taxol in advanced head and neck cancer: an Eastern Cooperative Oncology Group trial. Monogr Natl Cancer Inst 1993;15:181-4.
142. Dunphy F, Boyd J, Kim H, et al. Preoperative (PREOP) chemotherapy (CH) with paclitaxel/carboplatin (P/C) in head and neck cancer (HNCA): preliminary results of a phase II trial [abstr]. Proc Am Soc Clin Oncol 1997;16:399a.
143. Wanebo HJ, Chougule P, Akerley W, et al. Preoperative paclitaxel, carboplatin and radiation in advanced head and neck cancer (stage III and IV) induces a high rate of complete pathologic response (CR) at the primary site and high rate of organ preservation [abstr]. Proc Am Soc Clin Oncol 1997;16:391a.
144. Rosenthal DI, Carbone DP. Taxol plus radiation for head and neck cancer. J Infus Chemother 1995;5:46-54.
145. Aisner J, Belani CP, Kearns C, et al. Feasibility and pharmacokinetics of paclitaxel, carboplatin, and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced non-small cell lung cancer. Semin Oncol 1995;22(5 suppl 12):17-21.
146. Vokes EE, Haraf DJ, Stenson K, et al. The role of paclitaxel in the treatment of head and neck cancer. Semin Oncol 1995;22(5 suppl 12):8-12.
147. Janinis J, Papadakou M, Panagos G, et al. A phase II study of combined chemotherapy with docetaxel, cisplatin and 5-fluorouracil (5-FU) in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) and nasopharyngeal carcinoma (NC) [abstr]. Proc Am Soc Clin Oncol 1997;16:402a.
148. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993;20(4 suppl 3):1-15.
149. Peereboom DM, Donehower RC, Eisenhauer EA, et al. Successful re-treatment with Taxol after major hypersensitivity reactions. J Clin Oncol 1993;11:885-90.
150. Hilkens PHE, Pronk LC, Verweij J, Vecht CJ, van Putten WLJ, van den Bent MJ. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer 1997;75:417-22.
151. New PZ, Jackson CE, Rinaldi D, Burris H, Barohn RJ. Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 1996;46:108-11.
152. Lipton RB, Apfel SC, Dutcher JP, et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989;39: 368-73.
153. Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of Taxol. J Clin Oncol 1991;9:1704-12.
154. Arbuck SG, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with Taxol. Monogr Natl Cancer Inst 1993;15:117-30.
155. Cortez JE, Pazdur R. Docetaxel. J Clin Oncol 1995;13: 2643-55.
156. Zimmerman GC, Keeling JH, Burris HA, et al. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 1995;131:202-6.